VRTX: Summary for Vertex Pharmaceuticals Incorpor - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Thursday, September 2, 2010, 10:44am EST - Canadian Markets close in 5 hours and 16 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Vertex Pharmaceuticals Inc. (VRTX)

At 10:29 EST: 34.83 USD

0.08 (0.23%)

MORE ON VRTX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Vertex Pharmaceuticals Incorpor (NasdaqNM:VRTX) Delayed quote data

Last Trade:	34.83 USD
Trade Time:	10:29AM EST
Change:	0.08 (0.23%)
Prev Close:	34.91
Open:	34.65
Bid:	34.85 x 200
Ask:	34.87 x 100
1y Target Est:	33.85

Day's Range:	34.42 - 34.80
52wk Range:	31.25 - 44.24
Volume:	206,242
Avg Vol (3m):	1,428,340
Market Cap:	7.06B
P/E (ttm):	N/A
EPS (ttm):	-2.62
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add VRTX to Portfolio

Download Data

HEADLINES

•	Biotech Calendar: Key Dates for September
	at TheStreet.com (Wed 7:00am)

•	Pipeline Checkup: Merck Has Potential
	at Motley Fool (Mon, Aug 30)

•	Drug Prices Up, but Don't Read Too Much Into It
	at Motley Fool (Thu, Aug 26)

•	Biotech's Missteps and Milestones
	at Minyanville (Wed, Aug 18)

•	The Race Is On For Hepatitis C Treatment
	Investor's Business Daily (Fri, Aug 13)

•	New Hepatitis Therapy Could Be Vertex's Windfall
	at Seeking Alpha (Fri, Aug 13)

•	Dang! This Drug Is Shining Brighter
	at Motley Fool (Wed, Aug 11)

•	Pharma Stories You May Have Missed
	at Forbes (Wed, Aug 11)

•	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Genuity 30th Annual Growth Conference
	Business Wire (Tue, Aug 10)

•	Vertex: shorter hep C regimen OK
	at bizjournals.com (Tue, Aug 10)

More Headlines for VRTX...

ANALYST

EPS Est (next year) (Dec-07) :	-3.03
EPS Est (in 2 years) (Dec-08) :	-2.71
Avg Rec (current)*:	2.6
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide.

Full Company Profile

Add to Portfolio

Email to a Friend

•